Medical Licensing (MD/DO) · Independent exam preparation
FRCR Clinical Oncology: Scientific Reasoning and Clinical Decisions Study Guide
Practise radiobiology, treatment selection, radiation calculations and acute oncology decisions across the First and Final FRCR clinical oncology pathway.
By CertMedbry · Updated 18 October 2026
Connect tumour biology with treatment selection, calculate radiation and trial effects, and practise decisions about staging, planning, toxicity and urgent cancer care. This selective 60-concept guide covers the RCR clinical oncology fellowship pathway: First FRCR, Final FRCR Part A and Final FRCR Part B. The official curriculum and examination outlines define the full scope; these concepts provide a structured foundation for deeper study and supervised clinical practice.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination pathway does this guide cover?
The RCR clinical oncology pathway comprises First FRCR, labelled CO1; Final FRCR Part A, labelled CO2A; and Final FRCR Part B, labelled CO2B. The RCR also lists Joint Final Examinations in Clinical Oncology held in Hong Kong alongside the UK examinations.
How many questions and how much time are specified for First FRCR?
The four SBA modules are Cancer Biology and Radiobiology: 50 questions in 2.5 hours; Clinical Pharmacology: 40 questions in 2 hours; Physics: 50 questions in 2.5 hours; and Medical Statistics: 40 questions in 2 hours. These total 180 questions across the modules.
Which item styles are used, and how do these drills differ?
First FRCR uses five-option single-best-answer questions. Final Part A comprises two SBA papers. The 20 questions here use four options for independent learning. They do not reproduce Part B clinical performance, contouring or communication assessment and do not predict a pass.
FRCR Part 1 (Oncology) — guidance notes for candidates · Final FRCR Exam (Oncology) — purpose of assessment statement
What does Final FRCR Part A cover?
Paper 1 groups respiratory, urology, head and neck, skin, CNS and gynaecological oncology. Paper 2 groups breast, lower gastrointestinal, upper gastrointestinal, haematology, miscellaneous and image-based content. Sampling reflects curriculum scope and disease incidence; the purpose statement does not specify numerical tumour-topic percentages.
Final FRCR Exam (Oncology) — purpose of assessment statement
What structure and skills are assessed in Final FRCR Part B?
The blueprint lists ten tumour-site stations, one communication station and one contouring station, each with three skill assessments: 36 assessments overall. The skill totals are communication 5, clinical judgement 7, radiotherapy management 10, interpretation 5, patient-centred care 4 and SACT management 5. These are assessment counts, not tumour-topic percentages.
FRCR Part 2B (Oncology) — assessment blueprint · CO2B exam blueprint
Which curriculum dates and supplementary outlines apply?
The curriculum cover and RCR webpage specify implementation on 5 August 2026. The webpage calls the linked document Clinical Oncology Curriculum 2021, updated 4 August 2026; the document cover says August 2026. Section 6.3 also describes an update on 1 September 2026, an unresolved internal date discrepancy. The currently linked First FRCR supplement bears Curriculum 2021 and January 2020 labels. Its topic tables are illustrative rather than exhaustive or equally weighted.
Clinical oncology curriculum · Clinical Oncology Specialty Training Curriculum — August 2026 · Guidance for the first FRCR examination
How are topics allocated in this guide?
This guide uses an editorial breadth allocation: 28 science concepts, 22 tumour-specific concepts and 10 clinical-skills concepts. Within science, the allocation of 8 biology, 6 pharmacology, 8 physics and 6 statistics concepts approximates the First FRCR question shares of 27.8%, 22.2%, 27.8% and 22.2%. The questions and cards each contain 10 science, seven tumour-specific and three clinical-skills items. These allocations are not official combined pathway weights or a complete representation of the syllabus.
FRCR Part 1 (Oncology) — guidance notes for candidates · Final FRCR Exam (Oncology) — purpose of assessment statement · Clinical Oncology Specialty Training Curriculum — August 2026
How should the references and practice results be used?
Use the official RCR curriculum and examination outlines as the complete study map. Use drill errors to identify topics requiring further study and practical supervision. Clinical treatment evidence does not by itself establish UK commissioning eligibility. Consult current RCR candidate information for entry requirements, bookings and examination-day arrangements.
Clinical Oncology Specialty Training Curriculum — August 2026 · Clinical oncology exams · NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
FRCR clinical oncology is a specialist fellowship examination pathway. It is distinct from FRCR clinical radiology, medical oncology specialty examinations and general medical licensing. These independently authored learning materials are not official RCR questions or an endorsed examination simulator.
Outline used: Verified against the Clinical Oncology Specialty Training Curriculum, August 2026, implemented 5 August 2026, and the currently published RCR examination guidance and assessment blueprints, accessed 2026-10-10. The workbook's singular examination label maps to the clinical oncology FRCR pathway: First FRCR (CO1), Final FRCR Part A (CO2A), and Final FRCR Part B (CO2B). It is not a separate examination. The assigned slug is preserved. The 2026 curriculum appendix also describes an update dated 1 September 2026; this internal date discrepancy is retained rather than resolved by assumption.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Cancer Biology and Radiobiology (First FRCR)27.8% of First FRCR questions (50/180); pathway-wide weight not stated
1.How do oncogene activation and tumour-suppressor loss differ?
An oncogene promotes malignant behaviour through increased or inappropriate activity, whereas a tumour-suppressor gene normally restrains growth or preserves cellular integrity. An activating alteration in one oncogene allele can drive signalling. Many tumour suppressors require functional loss of both alleles within a cell. This distinction explains why a tumour-promoting molecular change may involve either excessive signalling or removal of a protective checkpoint, rather than simply increased expression of every cancer-associated gene.
Apply it
A molecular report describes an activating receptor mutation in one tumour allele and loss of both copies of a separate growth-control gene. Classify the first as oncogene activation and the second as tumour-suppressor inactivation.
Common pitfall: Do not equate dominant familial inheritance with a single cellular hit. Inheritance patterns across families and allele requirements within tumour cells describe different levels.
MedlinePlus Genetics — Retinoblastoma · Guidance for the first FRCR examination
2.Why can an inherited RB1 alteration produce multiple retinoblastomas?
A child with a germline pathogenic RB1 variant already carries one impaired copy in cells throughout the body. A retinal cell can form a tumour after a further somatic event disables the remaining functional copy. Because many retinal cells are at risk of that second event, hereditary disease is more likely to be bilateral or multifocal. A tumour containing RB1 alterations alone does not establish that an alteration is present in the germline.
Apply it
An infant has bilateral retinal tumours, while an older child has a single unilateral tumour. The bilateral presentation strengthens suspicion of germline predisposition and supports genetic assessment rather than relying on tumour laterality alone.
Common pitfall: Unilateral disease does not exclude hereditary retinoblastoma. Likewise, a negative family history does not exclude a newly arising germline pathogenic RB1 variant.
3.Which DNA lesions most threaten reproductive cell survival after irradiation?
Ionising radiation can damage DNA directly or through reactive products of water radiolysis. Double-strand breaks are especially important because inaccurate repair can produce lethal chromosome abnormalities. Cell survival depends on lesion complexity, repair capacity and subsequent division, not merely the number of initial breaks. Reproductive death means loss of sustained clonogenic capacity; an irradiated cell can remain metabolically active temporarily despite being unable to generate a continuing colony.
Apply it
Two irradiated cell cultures retain similar short-term metabolic activity, but one produces far fewer colonies after several divisions. Interpret this as reduced clonogenic survival rather than evidence that the radiation caused no meaningful cellular injury.
Common pitfall: Do not use immediate cell appearance or short-term viability as a complete measure of radiotherapy effect. Delayed reproductive failure can dominate the response.
4.Why does hypoxia reduce the effectiveness of low-LET radiation?
Oxygen can react with radiation-induced DNA radicals and make the resulting damage less chemically reversible. Hypoxic cells therefore generally require a higher low-linear-energy-transfer radiation dose for the same biological effect. The oxygen enhancement ratio compares doses under hypoxic and oxygenated conditions for an equal endpoint. It is a biological dose ratio, not a measurement of oxygen saturation, and its magnitude depends on radiation quality and the conditions of measurement.
Apply it
A laboratory compares clonogenic survival in matched cultures exposed to photons under oxygenated or severely hypoxic conditions. If hypoxic cells survive better at the same dose, oxygen fixation provides the relevant explanation.
Common pitfall: Do not interpret hypoxia as complete radiation resistance. Radiation can still cause lethal damage without oxygen, and the oxygen effect varies with radiation quality.
5.How does fraction size influence late normal-tissue effects?
In the linear-quadratic model, biological effect contains components proportional to dose and dose squared. Tissues with a low alpha/beta ratio show greater sensitivity to fraction size. Increasing dose per fraction can therefore increase late normal-tissue injury disproportionately, even when total physical dose falls. Comparing schedules requires a stated tissue endpoint and model assumptions; the same physical dose delivered in different fractions is not automatically biologically equivalent for tumour control and every normal tissue.
Apply it
A proposed schedule uses fewer, larger fractions near a late-responding organ. Before accepting a lower total dose as safer, compare biological dose using an appropriate alpha/beta assumption and assess the actual organ dose distribution.
Common pitfall: Do not assume every tumour has a high alpha/beta ratio or that linear-quadratic comparisons remain equally reliable at all fraction sizes and clinical settings.
6.How can reoxygenation improve tumour response during fractionated radiotherapy?
A tumour contains cells with different oxygen availability. After irradiation, changes in cell consumption, tumour architecture and perfusion can allow surviving hypoxic cells to become better oxygenated before later fractions. These cells may then become more sensitive to subsequent low-LET radiation. Reoxygenation is one reason a fractionated course cannot be understood simply as repeatedly treating an unchanged population, although its extent differs among tumours and does not guarantee elimination of hypoxia.
Apply it
A tumour initially contains a resistant hypoxic compartment. During a fractionated course, some surviving cells receive improved oxygen supply. Explain why their sensitivity to later photon fractions may increase without any change in the beam energy.
Common pitfall: Reoxygenation concerns changing tumour oxygenation between fractions. It should not be confused with repair of radiation damage, which can improve the survival of irradiated cells.
7.Why can prolonging a radical radiotherapy course reduce tumour control?
Surviving tumour clonogens can proliferate during treatment. In some rapidly proliferating cancers, accelerated repopulation during a prolonged course can offset part of the accumulated radiation effect. Consequently, identical total dose and fraction size do not guarantee identical tumour control when overall treatment time differs. Managing a treatment interruption requires assessment of tumour site, interruption timing, normal-tissue limits and the feasibility of a safe compensation strategy rather than an automatic extra fraction.
Apply it
A patient undergoing radical head-and-neck radiotherapy misses several treatment days because of an equipment failure. Review the effect on overall treatment time and seek a tumour-specific compensation plan that also respects normal-tissue constraints.
Common pitfall: Do not compensate for every gap by adding an arbitrary dose. The biological consequences and safe options depend on treatment context and cumulative normal-tissue exposure.
Radiation Biology: A Handbook for Teachers and Students · Clinical Oncology Specialty Training Curriculum — August 2026
8.How do acute reactions differ from late radiation injury?
Acute reactions commonly involve rapidly renewing tissues, where loss of proliferating cells compromises replacement of mature cells during or soon after treatment. Late injury can involve vascular, stromal and organ-specific changes that emerge months or years later. Their dose-response and fraction-size sensitivity differ. A mild acute reaction does not establish a low late-effect risk, because late injury depends on factors including fractionation, exposed volume and the functional organisation of the organ.
Apply it
A patient has little visible skin reaction during radiotherapy but receives substantial dose to an adjacent late-responding organ. Continue to assess that organ's dose constraints rather than treating the mild skin response as evidence of universal tolerance.
Common pitfall: Do not assume every late effect is merely an acute reaction that failed to heal. Some late injuries arise through different tissue processes and endpoints.
Clinical Pharmacology (First FRCR)22.2% of First FRCR questions (40/180); pathway-wide weight not stated
9.How does tamoxifen inhibit hormone-responsive breast cancer?
Tamoxifen is a selective oestrogen receptor modulator. Its anti-oestrogenic action in breast tissue interferes with receptor-mediated transcription and growth signalling in oestrogen receptor-positive cancer. It does not primarily work by stopping aromatase-mediated oestrogen synthesis. Receptor expression therefore provides a mechanistic reason to consider endocrine treatment, while the drug's tissue-dependent actions help explain why activity and adverse effects cannot be inferred from a simple description as an oestrogen blocker.
Apply it
A learner explains that tamoxifen treats an oestrogen receptor-positive tumour by eliminating ovarian oestrogen production. Correct the explanation: its relevant action is modulation of the oestrogen receptor rather than direct ovarian suppression.
Common pitfall: Do not substitute tamoxifen's mechanism for that of an aromatase inhibitor. Both are endocrine treatments, but they intervene at different points in the pathway.
NCI Drug Dictionary — Tamoxifen citrate · NCI — Hormone Therapy for Breast Cancer
10.Why does ovarian function matter when selecting an aromatase inhibitor?
Aromatase inhibitors reduce oestrogen synthesis by blocking conversion of androgens to oestrogens. This is particularly relevant after menopause, when peripheral aromatisation is an important oestrogen source. With functioning ovaries, aromatase inhibition alone is not an adequate substitute for ovarian suppression. Menopausal and ovarian function must therefore be established when constructing an endocrine strategy; absence of menstrual bleeding after chemotherapy does not by itself reliably establish permanent loss of ovarian function.
Apply it
A previously premenopausal patient has amenorrhoea after chemotherapy and is being considered for an aromatase inhibitor. Assess ovarian function and whether ovarian suppression is required rather than assuming that amenorrhoea establishes permanent menopause.
Common pitfall: Do not equate chronological age, temporary amenorrhoea and confirmed menopause. An aromatase inhibitor's suitability depends on the endocrine setting and accompanying ovarian management.
11.How does a sensitising EGFR mutation guide targeted treatment?
Some activating EGFR mutations make a lung cancer dependent on abnormal receptor tyrosine-kinase signalling and can predict sensitivity to an appropriate EGFR inhibitor. The relevant information is the specific molecular alteration and clinical setting, rather than receptor presence alone. Different EGFR alterations do not have identical treatment implications. A targeted treatment decision must therefore connect the variant, disease stage and treatment history with evidence for the proposed inhibitor instead of treating all EGFR findings as interchangeable.
Apply it
Two lung tumours are described as EGFR-positive: one has receptor staining, while the other has a documented sensitising mutation. The molecularly defined alteration provides the stronger basis for discussing an appropriate mutation-directed inhibitor.
Common pitfall: Do not infer inhibitor sensitivity from an EGFR label without identifying the alteration. Protein expression, sensitising mutations and resistance alterations answer different clinical questions.
NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
12.How do immune checkpoint inhibitors restore antitumour activity?
Immune checkpoints normally help restrain immune responses and protect healthy tissues. Tumours can exploit pathways such as PD-1 and PD-L1 to suppress T-cell activity. Blocking PD-1-mediated inhibitory signalling permits greater T-cell activity and can enable an antitumour response. The same reduction in immune restraint explains why treatment can cause inflammation in normal organs, including organs distant from the tumour or radiation field.
Apply it
A patient asks why an antibody aimed at an immune checkpoint can affect a tumour without binding a conventional growth-factor receptor. Explain that the treatment blocks immune inhibition and enables immune cells to attack cancer.
Common pitfall: Do not assume immune activation is confined to the tumour. Checkpoint inhibition can produce inflammatory toxicity in multiple organs, even when tumour response is favourable.
13.How do oxaliplatin's cytotoxic mechanism and limiting toxicity affect treatment?
Oxaliplatin forms platinum-DNA crosslinks that interfere with DNA replication and transcription, as described in the [NCI drug definition](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/oxaliplatin). A clinically important cumulative toxicity is peripheral sensory neuropathy, which can limit continued treatment. Assess persistent numbness and functional effects separately from tumour response. Disabling neuropathy may justify reducing, withholding or discontinuing oxaliplatin even when the regimen is controlling cancer; the decision balances recurrence or progression risk against potentially lasting neurological harm.
Apply it
During an oxaliplatin-containing regimen, a patient develops persistent finger numbness and difficulty fastening buttons despite tumour shrinkage. Assess sensory function and cumulative toxicity before further dosing rather than using the response alone to justify unchanged treatment.
Common pitfall: Do not equate drug activity with tolerability. A favourable scan does not protect against cumulative neuropathy or establish that every component should continue unchanged.
Guidance for the first FRCR examination · NCI — Colon Cancer Treatment (PDQ), Health Professional Version
14.How does clearance determine systemic drug exposure?
Area under the plasma concentration-time curve, or AUC, measures systemic exposure. For a single intravenous dose with linear pharmacokinetics, constant clearance and complete accounting of exposure, AUC = dose/clearance. A hypothetical 100 mg dose with clearance of 5 L/hour gives an AUC of 20 mg·hour/L. If clearance falls to 2.5 L/hour, the same dose gives 40 mg·hour/L: exposure doubles. Clearance describes elimination capacity, while pharmacodynamic sensitivity determines the biological effect of that exposure.
Apply it
For the hypothetical drug, maintaining an AUC of 20 mg·hour/L when clearance falls to 2.5 L/hour would mathematically require 50 mg. Apply this as a model calculation, not a universal clinical dose-adjustment rule; actual drug kinetics and validated dosing guidance must match the assumptions.
Common pitfall: Do not assume the same administered dose produces the same exposure. Oral bioavailability, nonlinear elimination, changing clearance and active metabolites can invalidate a simple intravenous dose/clearance calculation.
Physics (First FRCR)27.8% of First FRCR questions (50/180); pathway-wide weight not stated
15.Which radiation quantities use gray, sievert and becquerel?
Absorbed dose is energy imparted per unit mass and is measured in gray, with one gray equal to one joule per kilogram. Activity measures nuclear transformations per second and is expressed in becquerel. Equivalent and effective dose use sievert and incorporate radiation or tissue weighting for protection purposes. These quantities answer different questions: source activity alone does not specify a patient's absorbed dose, which also depends on emissions, geometry, uptake and time.
Apply it
A report lists an administered radionuclide activity in megabecquerels and an organ absorbed dose in gray. Explain why the values cannot be directly compared or converted without information about emissions and their deposition in tissue.
Common pitfall: Do not use sievert as a generic replacement for gray in therapeutic dose prescriptions. Protection quantities and absorbed treatment dose have different definitions and purposes.
Radiation Oncology Physics: A Handbook for Teachers and Students
16.How does the inverse-square law change dose rate with distance?
For an ideal point source in free space, intensity varies inversely with the square of distance: I2/I1 equals (r1/r2) squared. Doubling distance therefore reduces intensity to one quarter. The relationship describes geometric spreading and does not incorporate attenuation, scatter or changes in irradiated medium. A calculation must state its assumptions before it is applied to a clinical beam, where patient depth and treatment geometry can introduce additional effects.
Apply it
An ideal source produces a dose rate of 12 units at 1 metre. At 2 metres, with attenuation and scatter neglected, predict 3 units by multiplying the original value by the squared distance ratio.
Common pitfall: Do not halve intensity when distance doubles. That uses an inverse-distance relationship and misses the area increase over which the radiation energy spreads geometrically.
Radiation Oncology Physics: A Handbook for Teachers and Students
17.How do half-value layers describe photon attenuation?
A half-value layer is the material thickness that reduces a specified photon beam intensity to one half under stated conditions. For a narrow monoenergetic beam with constant attenuation coefficient, each additional half-value layer halves the remaining intensity. Three such layers transmit one eighth. Broad-beam scatter and beam hardening can change the relationship in practice, so repeated identical attenuation steps require assumptions about beam energy distribution, geometry and what the detector measures.
Apply it
A narrow monoenergetic beam passes through four half-value layers of a uniform absorber. Calculate transmission as one half raised to the fourth power: one sixteenth, or 6.25%, of the original intensity.
Common pitfall: Do not subtract a fixed half of the original intensity for every layer. Each ideal half-value layer acts on the radiation remaining after previous attenuation.
Radiation Oncology Physics: A Handbook for Teachers and Students
18.Why is bolus used for some superficial radiotherapy targets?
Megavoltage photon beams exhibit a build-up region, so the dose near the surface can be lower than the dose at depth. Tissue-equivalent bolus adds material above the skin and shifts build-up towards the patient's surface. It can improve coverage when skin or superficial tissue is part of the intended target. Bolus thickness, placement and air gaps affect the delivered distribution, making it a planned treatment component rather than a universal protective layer.
Apply it
A superficial target is undercovered by a megavoltage photon plan because of skin sparing. Consider planned tissue-equivalent bolus and verify its placement, rather than assuming that increasing beam energy will improve the surface dose.
Common pitfall: Bolus commonly increases surface dose rather than shielding skin. Adding it without planning can increase skin toxicity or alter coverage of deeper tissues unexpectedly.
Radiation Oncology Physics: A Handbook for Teachers and Students
19.How does brachytherapy geometry differ from external-beam treatment?
Brachytherapy places a sealed radiation source within or close to the treatment region, producing a steep dose gradient around the source. This can concentrate dose locally while limiting exposure farther away. External-beam treatment delivers radiation from outside the patient and shapes dose through beam arrangement and modulation. In brachytherapy, small differences in applicator or source position can materially change target and organ doses, so geometry verification is integral to interpreting a plan.
Apply it
Two brachytherapy plans use the same nominal prescription, but one applicator lies closer to a nearby organ. Compare the resulting dose distributions rather than assuming that equal prescription doses imply equal organ exposure.
Common pitfall: Do not treat a brachytherapy prescription as independent of source geometry. Distance, dwell positions and surrounding anatomy strongly influence the actual dose distribution delivered.
Radiation Oncology Physics: A Handbook for Teachers and Students · Clinical Oncology Specialty Training Curriculum — August 2026
20.What physical advantage and uncertainty distinguish proton therapy?
Protons deposit energy along a finite range, with a pronounced Bragg peak near the end of that range. Appropriately combined energies can cover a target while reducing exit dose compared with photons. This physical advantage is accompanied by sensitivity to range uncertainty, tissue changes and setup. A proton plan should therefore be assessed for robustness and organ sparing in the actual clinical geometry; reduced exit dose does not automatically establish superiority for every patient.
Apply it
A target lies immediately before a critical structure along a proposed proton beam direction. Assess range uncertainty and robust dose distributions, because an apparently favourable nominal distal dose fall-off may shift with anatomical changes.
Common pitfall: Do not assume the Bragg peak removes all normal-tissue dose. Entrance dose remains, and uncertainty at the end of range can be clinically important.
Radiation Oncology Physics: A Handbook for Teachers and Students · Clinical Oncology Specialty Training Curriculum — August 2026
21.How do physical and biological clearance determine effective half-life?
Physical half-life describes radioactive decay, while biological half-life describes removal of a substance from the relevant biological compartment. When both follow independent exponential processes, their removal constants add, so 1/Teffective equals 1/Tphysical plus 1/Tbiological. The effective half-life is therefore shorter than either component alone. The calculation depends on the compartment and kinetic assumptions; a single effective half-life may not adequately represent complex uptake, redistribution and clearance in every organ.
Apply it
A radionuclide has a physical half-life of six days and biological half-life of three days in a specified compartment. Under independent exponential clearance, calculate an effective half-life of two days for that compartment.
Common pitfall: Do not average the two half-lives or add them together. Independent decay and clearance act simultaneously, making effective retention shorter rather than longer overall.
Radiation Oncology Physics: A Handbook for Teachers and Students · Internal Exposure and Radioactive Materials [MOE]
22.Why does unsealed radionuclide therapy require contamination precautions?
An unsealed radioactive substance can be distributed within the patient and may be excreted, creating contamination risks in addition to external exposure from emitted radiation. Protection therefore considers time, distance, shielding and control of radioactive material. Advice must match the radionuclide, emissions, activity, clearance and household circumstances. Precautions for an unsealed therapy cannot simply be copied from external-beam treatment, where the patient ordinarily does not retain the treatment radiation source after exposure.
Apply it
A patient receiving unsealed radionuclide therapy asks whether the same advice applies as after a previous external-beam course. Explain that retained activity and possible radioactive excretion require treatment-specific instructions for contact and hygiene.
Common pitfall: Do not base precautions on administered activity alone. Emission type, physical decay, biological clearance and the patient's practical circumstances also influence exposure and contamination control.
Radiation Oncology Physics: A Handbook for Teachers and Students · Clinical Oncology Specialty Training Curriculum — August 2026
Medical Statistics (First FRCR)22.2% of First FRCR questions (40/180); pathway-wide weight not stated
23.How do randomisation and allocation concealment reduce trial bias?
Randomisation assigns treatment by chance and supports comparable groups on average, including for unknown prognostic factors. Allocation concealment prevents recruiters from knowing the next assignment before a participant enters the trial, reducing selective enrolment. Blinding addresses a different problem by limiting knowledge of assigned treatment after allocation. These safeguards serve complementary purposes; describing a trial as randomised does not establish that recruitment was concealed, subsequent assessments were blinded or chance baseline imbalance was impossible.
Apply it
A recruiter can see the next treatment assignment and delays enrolling a frail patient until the preferred arm is available. Identify compromised allocation concealment, even if the underlying sequence was originally generated at random.
Common pitfall: Do not use randomisation, concealment and blinding as interchangeable labels. Each controls a different opportunity for bias, and each requires separate appraisal in a trial.
24.Why analyse participants according to their randomised treatment group?
An intention-to-treat approach seeks to retain participants in their assigned groups, preserving the comparison created by randomisation. Excluding participants because they stopped treatment or crossed over can introduce bias when those events relate to prognosis. The analysis population, treatment discontinuation and missing outcomes must still be handled transparently. Assignment-based analysis does not make absent data disappear, and a full analysis set may require justified practical decisions that should be specified before examining results.
Apply it
Several participants stop an experimental treatment because of early toxicity. Keeping their subsequent outcomes in the assigned experimental group better preserves the randomised comparison than removing them because they did not complete treatment.
Common pitfall: Do not interpret intention-to-treat as permission to ignore missing outcomes. Retaining treatment assignment and addressing incomplete outcome information are related but separate analytical responsibilities.
25.How do absolute benefit and number needed to treat relate?
For a specified adverse outcome over a fixed period, absolute risk reduction is control risk minus treatment risk. Number needed to treat is the reciprocal of that reduction expressed as a proportion. If risks are 20% and 15%, the absolute reduction is 5 percentage points and NNT is 20. Interpretation requires a defined endpoint, follow-up period and appropriate risk estimates; relative reductions alone cannot reveal how many patients are likely to benefit.
Apply it
With complete three-year follow-up, recurrence occurs in 30% of controls and 20% of treated patients. Calculate a 10-percentage-point absolute reduction and an NNT of 10 over three years for that recurrence endpoint.
Common pitfall: Do not invert the percentage number directly or confuse relative and absolute reductions. An NNT without its endpoint and time horizon is incomplete and potentially misleading.
Guidance for the first FRCR examination · ICH E9 — Statistical Principles for Clinical Trials
26.What does a confidence interval establish about a treatment effect?
A confidence interval expresses uncertainty around an effect estimate under the chosen statistical model. For a hazard ratio, the no-difference value is one; for a risk difference, it is zero. An interval crossing the relevant null value does not establish equivalence. Type I error is falsely rejecting a true null hypothesis, and unplanned multiple testing increases opportunities for such errors. Interpretation should consider interval width, clinical importance and the prespecified testing strategy together.
Apply it
A superiority trial reports a hazard ratio of 0.82 with a 95% confidence interval of 0.63 to 1.07. Explain that the estimate favours treatment, but the interval includes no difference and does not prove equivalence.
Common pitfall: Do not describe a frequentist 95% interval as a 95% probability that this fixed parameter lies inside it. Its coverage concerns repeated use of the method.
27.Why does disease prevalence change a screening test's positive predictive value?
Sensitivity is the proportion of people with disease who test positive, while specificity is the proportion without disease who test negative. Positive predictive value asks a different question: among positive results, how many truly have disease? At fixed sensitivity and specificity, lower prevalence usually lowers positive predictive value because false positives arise from a larger disease-free population. A highly sensitive test therefore does not automatically make a positive result strongly diagnostic in a low-prevalence setting.
Apply it
In 1,000 people, 10 have disease. A test detects nine of them but also gives 99 false positives. Its positive predictive value is 9 divided by 108, approximately 8.3%, despite high sensitivity.
Common pitfall: Do not reverse the conditional probability: the chance of a positive test given disease differs from the chance of disease given a positive test result.
28.How should censoring and hazard ratios be interpreted in survival analysis?
Censoring records that an individual's event time is only partly known, such as being event-free at the last reliable follow-up. Kaplan-Meier estimation uses the information available before censoring rather than treating that person as having an event. Standard interpretation depends on assumptions about censoring. A hazard ratio compares event rates over time under its model; it is not a direct ratio of median survival times or a fixed absolute survival benefit.
Apply it
A participant remains alive when follow-up ends and is censored at that date. Include their observed survival time up to censoring, rather than counting a death or assuming they survive indefinitely after the study.
Common pitfall: Do not infer that a hazard ratio of 0.70 means every patient lives 30% longer. Relative hazards and individual survival duration are different quantities.
ICH E9 — Statistical Principles for Clinical Trials · Guidance for the first FRCR examination
Tumour-specific Oncology: Final Part A Paper 1not stated
29.When is stereotactic radiotherapy relevant to early non-small-cell lung cancer?
Stereotactic body radiotherapy delivers a highly conformal ablative radiation course and is an important definitive option for appropriately staged early non-small-cell lung cancer when surgery is medically unsuitable. The decision depends on localised disease, tumour position, organ constraints and the ability to manage motion and verify treatment accurately. Medical inoperability does not by itself make treatment palliative. Conversely, a small lung lesion should not be assumed to be node-negative or metastatic-free without staging assessment.
Apply it
A patient has a peripheral, node-negative stage I lung cancer and severe respiratory disease that precludes surgery. Discuss stereotactic radiotherapy as a potentially definitive local option after assessing imaging, motion and normal-tissue constraints.
Common pitfall: Do not equate inability to undergo surgery with inability to receive curative treatment. Equally, avoid extrapolating a peripheral-tumour approach unchanged to every central lesion.
NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
30.Why can mediastinal nodal assessment change a lung cancer treatment plan?
Regional nodal involvement changes lung cancer stage and can alter suitability for surgery, radiotherapy fields and the need for multimodality treatment. Imaging identifies suspicious nodes but does not make every enlarged or metabolically active node malignant. When nodal status would change a major management decision, appropriate pathological assessment can resolve clinically important uncertainty. Staging is therefore a treatment-defining process, rather than merely a label attached after selecting a preferred local therapy.
Apply it
A potentially operable lung cancer has a suspicious mediastinal node on staging imaging. Establish whether further nodal sampling is needed before committing to a local-treatment pathway whose suitability depends on the nodal result.
Common pitfall: Do not treat imaging suspicion as histological certainty or dismiss a node because the primary tumour is small. Nodal findings require interpretation within the full staging context.
NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
31.How does active surveillance differ from watchful waiting in prostate cancer?
Active surveillance defers immediate treatment while monitoring selected localised prostate cancers, with curative treatment still considered if clinically important progression becomes apparent. Watchful waiting generally focuses on symptom-directed management rather than a structured pathway towards delayed curative intervention. Tumour risk, life expectancy, comorbidity and preferences help distinguish the appropriate approach. The same initial decision to avoid immediate treatment can therefore represent substantially different objectives and follow-up plans.
Apply it
A healthy patient with selected low-risk localised prostate cancer accepts regular reassessment and would consider curative treatment if risk increases. Describe this as active surveillance rather than symptom-led watchful waiting without a curative monitoring strategy.
Common pitfall: Do not use the two terms as synonyms for doing nothing. Their monitoring intensity, treatment triggers and underlying goals differ and should be explained explicitly.
NCI — Prostate Cancer Treatment (PDQ), Health Professional Version
32.Why is androgen suppression combined with radiotherapy in selected prostate cancers?
Prostate cancer growth commonly depends on androgen signalling. Androgen deprivation reduces this stimulus and can improve outcomes when integrated with radiotherapy in appropriate higher-risk or locally advanced disease. Its use is determined by disease risk and treatment context, rather than by the presence of any prostate cancer diagnosis. The expected oncological benefit must be balanced against systemic effects and comorbidity, and treatment duration cannot be inferred from mechanism alone.
Apply it
A patient with higher-risk localised prostate cancer is considering radiotherapy and asks why a systemic hormonal treatment is also discussed. Explain the complementary disease-control role and assess cardiovascular, metabolic and quality-of-life concerns.
Common pitfall: Do not extrapolate combined treatment to every low-risk tumour or assume androgen deprivation is equivalent to definitive local treatment when durable local control is intended.
NCI — Prostate Cancer Treatment (PDQ), Health Professional Version
33.How does HPV association affect interpretation of oropharyngeal cancer prognosis?
HPV-associated oropharyngeal squamous-cell carcinoma generally has a more favourable prognosis than HPV-unrelated disease, but outcome still depends on factors including stage and smoking exposure. HPV-related biology informs classification and prognostic discussion; it does not make the cancer benign or establish that a less intensive treatment is appropriate for an individual. Biomarker interpretation should therefore distinguish a prognostic association from evidence that a particular treatment can safely be reduced.
Apply it
A patient with HPV-associated oropharyngeal cancer asks whether favourable biology means treatment can be omitted. Explain the prognostic significance while maintaining a stage-appropriate treatment discussion rather than treating HPV positivity as proof of negligible risk.
Common pitfall: Do not convert a favourable prognostic marker into an automatic de-escalation instruction. Prognosis and evidence supporting a specific treatment modification are separate questions requiring evaluation.
NCI — Oropharyngeal Cancer Treatment (PDQ), Health Professional Version
34.How can IMRT reduce salivary toxicity in head-and-neck treatment?
Intensity-modulated radiotherapy varies beam fluence to shape dose around complex targets and spare selected normal structures. Reducing dose to functioning salivary tissue can lower the risk of xerostomia compared with less conformal approaches. The benefit depends on actual dose distributions and safe target coverage. A technique name does not guarantee organ sparing, and preserving a gland cannot justify deliberately excluding tumour or an indicated target region from adequate treatment.
Apply it
Two head-and-neck plans cover the target similarly, but one lowers dose to uninvolved salivary glands while respecting other constraints. Prefer the plan with the better therapeutic balance rather than choosing solely by the delivery technique's label.
Common pitfall: Do not prioritise salivary sparing above necessary tumour coverage. Dose reduction is useful when the gland can be spared without compromising the intended oncological treatment.
NCI — Oropharyngeal Cancer Treatment (PDQ), Health Professional Version
35.Which primary melanoma features help determine risk and further staging?
For cutaneous melanoma, Breslow thickness measures the depth of invasion and is a central component of primary tumour assessment. Ulceration adds prognostic information and contributes to staging. These pathological features help guide discussion of further nodal assessment and management alongside the clinical examination. A lesion's surface diameter or pigmentation cannot substitute for invasive depth, and absence of palpable nodes does not establish that regional nodes contain no microscopic disease.
Apply it
Two excised melanomas have similar surface diameter but different Breslow thickness and ulceration status. Use the pathological depth and ulceration findings to compare risk rather than assuming that equal visible size implies equivalent stage.
Common pitfall: Do not confuse Breslow thickness with the width of the skin lesion or the surgical excision margin. These describe different measurements with different management implications.
36.What does sentinel lymph-node biopsy establish in melanoma?
Sentinel lymph-node biopsy samples the node or nodes most likely to receive initial lymphatic drainage from the primary tumour. It can detect microscopic regional metastasis in clinically node-negative patients and refine pathological stage. The result informs prognosis and subsequent management discussions, but a negative result does not prove that dissemination is impossible. Its staging purpose should be distinguished from assuming that removing a sentinel node alone treats all potential regional or distant disease.
Apply it
A patient has a melanoma for which sentinel-node assessment is being discussed despite a normal nodal examination. Explain that the procedure investigates microscopic regional spread that palpation and routine clinical assessment may not detect.
Common pitfall: Do not describe a negative sentinel-node result as a guarantee against recurrence. Sampling has limitations, and tumour spread or later relapse remains possible after negative findings.
NCI — Sentinel Lymph Node Biopsy · NCI — Melanoma Treatment (PDQ), Health Professional Version
37.What can MRI establish when assessing a suspected primary brain tumour?
MRI defines lesion location, extent and relationships to critical brain structures and is central to assessment and treatment planning. Imaging patterns can suggest a diagnosis, but enhancement and signal characteristics are not complete substitutes for tissue and molecular classification when these are needed and obtainable. Interpretation must integrate symptoms, prior treatment and alternative causes of abnormal signal. A striking scan can therefore guide the next diagnostic step without independently establishing every feature of tumour type or grade.
Apply it
An MRI shows an enhancing intracranial mass. Use it to assess anatomy and plan multidisciplinary investigation, while avoiding a definitive molecular diagnosis based solely on enhancement or assuming that all enhancing tissue represents viable tumour.
Common pitfall: Do not equate radiological appearance with a complete integrated diagnosis. Imaging uncertainty can materially affect management, especially when treatment effects or alternative pathology are plausible.
NCI — Central Nervous System Tumors Treatment (PDQ), Health Professional Version
38.Why does MGMT promoter methylation matter in glioblastoma?
MGMT removes alkyl groups from the O6 position of guanine. Promoter methylation can reduce MGMT expression, making tumour cells less able to reverse this component of temozolomide-induced DNA damage. In glioblastoma, the finding has prognostic and treatment-response significance. It remains a probabilistic biomarker rather than a guarantee of benefit. Age, fitness, integrated diagnosis and treatment setting still matter when translating the molecular result into a management discussion.
Apply it
A glioblastoma specimen shows MGMT promoter methylation. Connect reduced O6-methylguanine repair with potential temozolomide sensitivity, while distinguishing the response association from the separate observation that methylated tumours often have a more favourable prognosis.
Common pitfall: Do not interpret methylation as increased MGMT repair activity or confuse MGMT with nucleotide-excision repair of platinum-DNA crosslinks.
NCI — Central Nervous System Tumors Treatment (PDQ), Health Professional Version
39.Why is brachytherapy important in definitive cervical cancer radiotherapy?
Brachytherapy places radiation sources close to the cervical tumour, enabling a high central dose with rapid dose fall-off towards surrounding organs. It is an integral component of many definitive radiation approaches for locally advanced cervical cancer. External-beam treatment and brachytherapy have complementary roles rather than being automatically interchangeable. Assessment must include target coverage, applicator geometry and dose to nearby organs, because a prescribed dose alone cannot establish the adequacy of the implant.
Apply it
A patient completing pelvic external-beam treatment asks whether brachytherapy is simply an optional duplicate. Explain its distinct local dose-delivery role and why its suitability and planning should be considered within the definitive treatment pathway.
Common pitfall: Do not assume a more conformal external-beam technique automatically reproduces brachytherapy's clinical role or dose geometry. Any alternative requires a justified specialist treatment strategy.
NCI — Cervical Cancer Treatment (PDQ), Health Professional Version
40.How does concurrent chemoradiotherapy differ from sequential treatment in cervical cancer?
Concurrent chemoradiotherapy gives systemic treatment during radiation, allowing a radiosensitising contribution as part of definitive management for suitable locally advanced cervical cancer. This differs from simply giving two modalities at unrelated times. Suitability depends on disease extent, organ function, performance status and treatment tolerance. The systemic component does not remove the need for adequate radiation delivery, including brachytherapy where indicated, and treatment selection must account for the combined toxicity burden.
Apply it
A fit patient with locally advanced cervical cancer is offered concurrent systemic treatment during definitive radiation. Explain the integrated radiosensitising purpose and review treatment tolerance rather than describing the systemic therapy as a replacement for brachytherapy.
Common pitfall: Do not assume concurrent treatment is appropriate regardless of organ function or fitness. Evidence for an integrated regimen must be applied alongside a patient-specific safety assessment.
NCI — Cervical Cancer Treatment (PDQ), Health Professional Version
49.Why does an adult medulloblastoma diagnosis change postoperative radiation planning?
Medulloblastoma can disseminate through cerebrospinal fluid, spreading beyond the primary tumour to other intracranial and spinal sites. Removing the visible posterior-fossa tumour therefore does not eliminate the risk of microscopic disease throughout the neuraxis. This biological behaviour explains why postoperative craniospinal irradiation, with additional treatment to the primary site, enters consideration in adults. A tumour-bed-only approach does not address the same distribution of potential disease. Confirmed pathology, dissemination assessment and the patient's clinical circumstances inform the treatment plan.
Apply it
An adult undergoes complete macroscopic resection of a medulloblastoma. Explain that the absence of visible residual tumour does not exclude microscopic cerebrospinal-fluid dissemination. Reassess a proposed focal-only plan and consider craniospinal treatment, a primary-site boost and the role of systemic therapy within specialist neuro-oncology planning.
Common pitfall: Do not infer the required treatment volume solely from the primary tumour's location or completeness of resection. Craniospinal consideration follows the tumour's dissemination pattern; it does not mean every adult receives an identical regimen or that adult treatment can be transferred unchanged to young children.
NCI — Central Nervous System Tumors Treatment (PDQ), Health Professional Version · Clinical Oncology Specialty Training Curriculum — August 2026 · Final FRCR Exam (Oncology) — purpose of assessment statement
Tumour-specific Oncology: Final Part A Paper 2not stated
41.Why is radiotherapy commonly given after breast-conserving surgery, and when has omission been studied?
Postoperative radiotherapy reduces recurrence from microscopic disease remaining in the breast despite clear surgical margins. Evidence example: CALGB 9343 studied women aged at least 70 with clinical stage I ER-positive disease receiving tamoxifen after lumpectomy. At ten years, freedom from local or regional recurrence was 98% with radiation and 90% without it; no significant survival difference was demonstrated. Omission therefore trades higher local recurrence risk against avoiding radiation in a selected population. Trial eligibility is not a universal UK omission rule.
Apply it
For a 74-year-old with a completely excised small, clinically node-negative ER-positive cancer who plans endocrine therapy, discuss the selected-trial evidence, local-control benefit, treatment burden and preferences. Age alone does not establish suitability for omission.
Common pitfall: Do not interpret absence of a demonstrated survival disadvantage as absence of a local-control benefit, or apply the trial result to younger patients or biologically different disease without supporting evidence.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version
42.How do hormone receptors and HER2 guide different breast cancer treatments?
Oestrogen and progesterone receptor findings identify hormone-responsive biology, whereas HER2 testing identifies a different growth-signalling pathway that may support HER2-directed therapy. These markers can coexist, so one positive result does not make the others irrelevant. Treatment selection combines biomarker results with stage, recurrence risk, prior treatment and patient factors. A pathology report should therefore be interpreted as a set of complementary predictive features rather than a single universal label of target positivity.
Apply it
A breast tumour is both oestrogen receptor-positive and HER2-positive. Consider the relevance of endocrine and HER2-directed strategies within its stage-specific plan rather than assuming that one positive marker excludes treatment directed at the other.
Common pitfall: Do not substitute hormone-receptor status for HER2 status or treat either marker as a complete treatment plan. Their biological targets and therapeutic implications are distinct.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version
43.Why is adjuvant chemotherapy considered after stage III colon cancer resection?
Regional lymph-node involvement identifies stage III colon cancer and indicates a risk of recurrence beyond the resected primary site. Adjuvant chemotherapy is considered to reduce that risk by treating occult residual disease. The rationale does not depend on a measurable postoperative tumour. Regimen selection and treatment burden require consideration of fitness and toxicity, while the distinction between colon and rectal cancer matters because their local-treatment pathways and use of radiotherapy differ.
Apply it
After complete colon cancer resection, pathology identifies involved regional nodes and postoperative imaging shows no metastases. Explain the adjuvant systemic-treatment rationale rather than waiting for visible recurrence before acknowledging a potential treatment benefit.
Common pitfall: Do not infer that an apparently complete resection removes systemic recurrence risk. Also avoid transferring rectal radiotherapy practices automatically to a resected colon cancer case.
NCI — Colon Cancer Treatment (PDQ), Health Professional Version
44.How does mismatch-repair status predict a treatment option in metastatic colorectal cancer?
Deficient mismatch repair allows replication errors to accumulate and commonly produces high microsatellite instability, or MSI-H. The resulting mutation burden can generate abnormal peptides recognised by the immune system. Metastatic dMMR/MSI-H colorectal cancer can therefore be sensitive to checkpoint inhibition, including pembrolizumab in an appropriate treatment setting. This is a predictive treatment association, not a guarantee of response. Tumour dMMR also raises hereditary-risk questions but does not itself diagnose Lynch syndrome; sporadic mechanisms can produce the same tumour phenotype.
Apply it
A patient with newly diagnosed metastatic colorectal cancer has confirmed dMMR/MSI-H disease. Consider pembrolizumab within the systemic-treatment discussion and assess hereditary risk separately. Treatment evidence does not establish current UK commissioning eligibility.
Common pitfall: Do not infer Lynch syndrome from tumour testing alone or extend the metastatic immunotherapy implication automatically to every resected-stage adjuvant decision.
NCI — Colon Cancer Treatment (PDQ), Health Professional Version · NCI — Immune Checkpoint Inhibitors
45.Which HER2 results support trastuzumab-based treatment in advanced gastric cancer?
For the advanced gastric cancer pathway described by NCI, HER2 positivity includes IHC 3+ or IHC 2+ with positive in-situ hybridisation, such as FISH demonstrating amplification. IHC 2+ alone is equivocal and requires the amplification result before it establishes this treatment-relevant classification. Confirmed positivity can support trastuzumab with chemotherapy in an appropriate advanced-disease setting. Gastric scoring criteria, disease stage, previous treatment and fitness remain relevant; treatment evidence and jurisdictional access requirements are separate.
Apply it
A metastatic gastric adenocarcinoma is IHC 2+ with FISH pending. Obtain the amplification result before assigning a HER2-positive trastuzumab pathway. An IHC 3+ result or IHC 2+/FISH-positive result supports that discussion.
Common pitfall: Do not interpret IHC 2+ alone as either confirmed positive or definitively negative, or assume a positive marker establishes eligibility for every HER2-directed drug and treatment line.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
46.How does malignant gastric obstruction change the immediate treatment goal?
Obstruction can prevent oral intake and cause substantial symptoms even when the broader disease is not curable. Palliation may require an intervention that directly restores passage or bypasses the obstructed segment, alongside nutritional and symptom support. The choice depends on anatomy, expected durability, prognosis and procedural fitness. Systemic treatment may address the cancer but cannot be assumed to relieve a mechanically significant obstruction quickly enough to meet the patient's immediate needs.
Apply it
A patient with advanced gastric cancer has persistent vomiting and cannot maintain oral intake because of obstruction. Assess a symptom-directed intervention such as endoscopic or surgical palliation rather than relying solely on a future systemic response.
Common pitfall: Do not label local palliation futile because metastatic disease is present. A focused intervention may provide important symptom relief without attempting to eradicate the underlying cancer.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
47.Which symptoms qualify as B symptoms in Hodgkin lymphoma?
B symptoms comprise unexplained fever above 38°C, drenching night sweats and unexplained loss of more than 10% of body weight over six months. These defined features add staging and prognostic information. Common complaints such as fatigue or pruritus are clinically relevant but do not independently satisfy the B-symptom definition. The history must establish the required severity, timing and lack of a better explanation rather than simply recording that constitutional symptoms are present.
Apply it
A patient with Hodgkin lymphoma reports itching, fatigue and a 12% unintentional weight loss over six months. The qualifying weight loss supports a B designation; itching and fatigue alone would not establish that suffix.
Common pitfall: Do not count every constitutional symptom as a B symptom. Mild sweating, an unspecified weight change or fever with a clear alternative cause requires careful interpretation.
NCI — Hodgkin Lymphoma Treatment (PDQ), Health Professional Version
48.How does the diaphragm help distinguish Hodgkin lymphoma stages?
Anatomical staging considers the distribution of involved nodal regions and extranodal disease. Nodal disease confined to one side of the diaphragm differs from nodal involvement on both sides, the latter supporting stage III. Disseminated extranodal organ involvement can indicate stage IV and should not be confused with limited direct extension from a nodal site. Stage describes distribution; symptom suffixes and other risk features provide additional information rather than replacing anatomical assessment.
Apply it
Imaging confirms Hodgkin lymphoma in cervical and para-aortic nodal regions without disseminated extranodal involvement. Recognise disease on both sides of the diaphragm as supporting stage III rather than classifying it solely by the number of nodes.
Common pitfall: Do not assign advanced stage simply because several nodes are enlarged within one region. Anatomical distribution and the nature of extranodal involvement determine the stage.
NCI — Hodgkin Lymphoma Treatment (PDQ), Health Professional Version
50.How should an FDG-avid mediastinal node be interpreted in an otherwise localised lung cancer?
Hypothetical imaging case: contrast CT shows a 2.4 cm spiculated right-upper-lobe tumour and a right lower paratracheal node measuring 14 mm in short axis. PET-CT shows FDG uptake in both, without distant lesions. Nodal enlargement and avidity support suspicion of ipsilateral mediastinal metastasis, which would represent N2 involvement. Inflammatory nodes can also enlarge and accumulate FDG, so neither feature proves malignancy. If this distinction changes treatment, nodal tissue assessment, such as EBUS-guided sampling, is needed.
Apply it
In a medically inoperable patient otherwise suitable for primary-only stereotactic treatment, review the suspicious paratracheal node before proceeding. Confirmed N2 disease changes stage and prompts a different treatment discussion; a negative sample must be assessed for adequacy and consistency with the imaging.
Common pitfall: Do not call an avid node malignant solely from PET or assume its location is hilar. Paratracheal anatomy makes it mediastinal, and imaging cannot establish its histology.
NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version · Clinical Oncology Specialty Training Curriculum — August 2026
Clinical Skills and Acute Oncology (Final FRCR)not stated
51.What must proceed alongside imaging for suspected malignant spinal cord compression?
In established metastatic cancer, new back pain with weakness, sensory change, gait disturbance or sphincter dysfunction requires urgent action for possible cord or cauda equina compression. Arrange urgent whole-spine MRI while starting prompt corticosteroid treatment, usually dexamethasone, to reduce associated oedema. Assess spinal stability and protect against movement that may worsen an unstable lesion. Seek urgent spinal surgical and oncology input for decompression or stabilisation in suitable patients and for radiotherapy planning. Neurological injury can become irreversible, so imaging must not postpone initial management.
Apply it
A patient with metastatic cancer develops thoracic pain, leg weakness and urinary difficulty. Initiate the emergency pathway, corticosteroids and stability precautions while arranging MRI and urgent assessment for surgery and/or radiotherapy.
Common pitfall: Do not wait for paralysis or an MRI report before initiating treatment in this established-cancer neurological presentation. Steroids do not correct mechanical instability or replace definitive local treatment.
52.How should new breathlessness and hypoxaemia during pembrolizumab treatment be assessed and managed?
Pembrolizumab blocks PD-1 signalling, increasing T-cell activity but potentially causing inflammatory injury to normal lung tissue. New respiratory symptoms require immediate assessment of respiratory effort, oxygenation and physiological stability, oxygen support for hypoxaemia, chest imaging and investigation for infection and competing causes such as pulmonary embolism, progression or cardiac disease. Hold pembrolizumab while suspected symptomatic pneumonitis is assessed. For established pneumonitis, pembrolizumab guidance specifies withholding treatment for grade 2, systemic corticosteroids for grade 2 or worse, and permanent discontinuation for grade 3–4 or recurrent grade 2 events.
Apply it
A patient receiving pembrolizumab develops breathlessness and reduced oxygen saturation. Arrange urgent clinical assessment, support oxygenation, obtain chest CT and investigate infection and other cardiopulmonary causes. Withhold the next pembrolizumab dose pending assessment. Severe respiratory compromise requires hospital care and escalation of respiratory support; suspected severe immune pneumonitis requires prompt corticosteroid treatment alongside investigation of competing causes.
Common pitfall: Checkpoint exposure alone does not establish pneumonitis. An unspecified oxygen saturation cannot determine its toxicity grade: symptoms, functional limitation, oxygen requirement and required interventions contribute to severity assessment. Distinguish temporary withholding for grade 2 from permanent discontinuation for grade 3–4 or recurrent grade 2 pneumonitis.
NCI — Immune Checkpoint Inhibitors · Clinical Oncology Specialty Training Curriculum — August 2026 · KEYTRUDA_imAEs_Guide.pdf
53.How should suspected neutropenic sepsis after SACT be managed before the blood count returns?
Recent SACT with fever or acute illness raises concern for infection with possible neutropenia. Hypotension, confusion, tachypnoea, hypoxia or reduced urine output indicate physiological danger; fever can be absent. Assess airway, breathing, circulation, mental state and urine output, obtain intravenous access and begin indicated resuscitation, including fluids with reassessment and oxygen for hypoxaemia. Send urgent full blood count, renal and liver tests, lactate and cultures. Give prompt empirical intravenous antibiotics without waiting for the neutrophil result or delaying for cultures.
Apply it
A patient eight days after cytotoxic treatment has a temperature of 38.5°C, blood pressure of 85/55 mmHg and confusion. Treat immediately as high-risk suspected sepsis, obtain investigations in parallel and escalate for senior and critical-care assessment. The Christie protocol targets antibiotics within one hour; antibiotic selection follows the applicable local policy, allergies and organ function.
Common pitfall: Do not wait for confirmed neutropenia, a positive culture or a high fever in a clinically unstable patient. Institutional antibiotic regimens and timing targets are clinical protocols, not separate RCR examination rules.
clinical-guidance-for-the-management-of-sepsis-including-neutropenic-sepsis.pdf · Clinical Oncology Specialty Training Curriculum — August 2026
54.How do GTV and CTV represent different disease burdens?
The gross tumour volume represents demonstrable macroscopic disease defined through examination and relevant imaging. The clinical target volume includes tissue requiring treatment for potential microscopic disease, which may extend beyond the visible abnormality. A postoperative setting can require a CTV even when no GTV remains. These are clinical disease definitions, not simply mechanical expansions: anatomical barriers, routes of spread and the treatment setting influence the appropriate volume.
Apply it
After complete tumour resection, no macroscopic lesion is visible on the planning scan, but the operative bed remains at risk of microscopic disease. Define an appropriate CTV rather than concluding that the absence of a GTV removes every target.
Common pitfall: Do not use GTV and CTV interchangeably or assume the CTV is always a uniform geometric margin. Its purpose is coverage of relevant microscopic disease risk.
Radiation Oncology Physics: A Handbook for Teachers and Students · FRCR Part 2B (Oncology) — assessment blueprint
55.How do ITV and PTV address different treatment uncertainties?
An internal target volume accounts for relevant internal movement and variation in target position or shape, such as respiration. A planning target volume is a geometrical concept used to help ensure that the intended clinical target receives the prescribed dose despite specified uncertainties, including setup variation. These volumes do not represent additional tumour spread. Motion assessment, immobilisation and image guidance inform margins; introducing a new verification method does not automatically justify removing every uncertainty allowance.
Apply it
A lung tumour moves with breathing despite reproducible external positioning. Address internal motion separately from daily setup variation, then justify the planning margin using the actual motion-management and verification strategy rather than relying on skin marks alone.
Common pitfall: Do not label a motion margin as microscopic disease or assume a stable external setup means the internal tumour remains fixed throughout breathing and treatment delivery.
Radiation Oncology Physics: A Handbook for Teachers and Students · FRCR Part 2B (Oncology) — assessment blueprint
56.How should target coverage and organ-at-risk dose be balanced?
Plan evaluation requires both adequate target coverage and acceptable exposure of relevant organs at risk. A single maximum dose, average dose or attractive isodose image cannot capture every clinically important feature. Interpretation should consider the organ's response, irradiated volume, fractionation and the location of hot or cold regions. When target and organ objectives conflict, the decision requires an explicit clinical trade-off rather than silently accepting undercoverage or ignoring a meaningful normal-tissue risk.
Apply it
A plan meets a headline target-coverage metric but contains a cold region at a high-risk tumour boundary and excessive dose near a critical organ. Review the spatial distribution and alternatives rather than approving it from summary percentages alone.
Common pitfall: Do not approve a plan solely because one numerical constraint passes. Dose-volume summaries must be interpreted with anatomy, treatment intent and clinically relevant spatial information.
Clinical Oncology Specialty Training Curriculum — August 2026 · Radiation Oncology Physics: A Handbook for Teachers and Students
57.How are BED and EQD2 calculated and used when assessing reirradiation?
The linear-quadratic model gives BED = nd[1 + d/(alpha/beta)] and EQD2 = BED/[1 + 2/(alpha/beta)]. Here n is the number of fractions, d is dose per fraction in Gy, nd is total physical dose, and alpha/beta is the tissue- and endpoint-specific ratio of radiosensitivity coefficients, expressed in Gy. BED is biologically effective dose; EQD2 is the equivalent total dose delivered in 2 Gy fractions. These basic equations assume equal fractions within each course and complete repair of sublethal damage between fractions, without a treatment-time correction.
Apply it
Suppose the same overlapping tissue receives 30 Gy in 10 fractions, then 20 Gy in five fractions, using alpha/beta = 3 Gy. The first course has BED = 30[1 + 3/3] = 60 Gy and EQD2 = 60/(1 + 2/3) = 36 Gy. The second has BED = 20[1 + 4/3] = 46.67 Gy and EQD2 = 28 Gy. Assuming no long-term tissue recovery between courses, cumulative EQD2 is 36 + 28 = 64 Gy.
Common pitfall: The 64 Gy result is a mathematical comparison, not an organ tolerance or a guarantee of safety. Confirm actual organ doses and spatial overlap from the plans rather than summing prescriptions or maxima at different locations. Clinical assessment also considers irradiated volume, organ endpoint, previous toxicity, elapsed time, possible recovery, dose-reconstruction uncertainty and expected benefit.
Clinical Oncology Specialty Training Curriculum — August 2026 · Radiation Biology: A Handbook for Teachers and Students
58.How should palliative radiotherapy be matched to a patient's symptoms?
Palliative radiotherapy aims to relieve a defined problem, such as pain or another local tumour-related symptom, with a treatment burden proportionate to expected benefit. Target selection should connect the symptom, examination and imaging rather than treating every visible metastasis. Fractionation and field design depend on anatomy, prior treatment, urgency, prognosis and practical circumstances. A technically elaborate plan is not automatically the best palliative choice if it delays relief or imposes disproportionate burden.
Apply it
A patient with widespread metastases has one clearly localised painful site and difficulty travelling. Identify the symptomatic target and a proportionate treatment strategy, rather than expanding treatment merely because additional asymptomatic lesions appear on imaging.
Common pitfall: Do not equate palliation with an imprecise field or an automatic regimen. Symptom attribution, normal-tissue protection and prior-dose review remain necessary for safe treatment.
Clinical Oncology Specialty Training Curriculum — August 2026 · FRCR Part 2B (Oncology) — assessment blueprint
59.How does teach-back reveal whether a treatment explanation was understood?
Teach-back asks the patient to explain key information in their own words so the clinician can assess the clarity of the explanation. It is most useful when framed as a check on communication, followed by clarification and another check if needed. Asking only whether the patient understands often produces agreement without demonstrating comprehension. Treatment purpose, important adverse effects and actions to take if problems occur are suitable topics for a focused teach-back discussion.
Apply it
After explaining treatment, ask the patient to describe its main aim and what they would do if a serious symptom develops. If the explanation is inaccurate, clarify the information and check understanding again without blaming the patient.
Common pitfall: Do not turn teach-back into a memory examination or demand exact medical terminology. The goal is usable understanding, and misunderstanding calls for a clearer explanation.
60.What makes consent and trial participation meaningfully informed?
Informed consent requires discussion of treatment purpose, expected benefits, important harms, reasonable alternatives and the option of no treatment, with attention to the person's priorities and understanding. Trial participation adds discussion of the research question and relevant uncertainty rather than presenting an experimental option as established superior care. The consultation should allow questions and adequate consideration. A signed form documents a process but cannot replace the communication needed to support a voluntary, informed decision.
Apply it
A patient believes trial entry guarantees the better treatment. Clarify the uncertainty being studied, explain the available standard options and explore whether participation fits the patient's priorities before seeking a decision or signature.
Common pitfall: Do not use a signature or an enthusiastic response as proof of informed choice. Misunderstanding of treatment intent or research uncertainty must be addressed explicitly first.
Clinical Oncology Specialty Training Curriculum — August 2026 · FRCR Part 2B (Oncology) — assessment blueprint · AHRQ — Use the Teach-Back Method: Tool 5
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Distinguish molecular mechanisms from clinical implications: receptor modulation, enzyme inhibition, DNA damage and repair, and immune disinhibition lead to different treatment and toxicity cues.
- Connect cytotoxic exposure and clearance with toxicity; assess cumulative sensory neuropathy separately from tumour response during oxaliplatin treatment.
- Practise physics with explicit assumptions, units and intermediate steps, particularly inverse-square scaling, repeated half-value layers and effective half-life.
- Interpret trial results using absolute effects, confidence intervals, analysis populations and the correct survival endpoint.
- For each tumour group, connect stage and biomarkers to treatment intent, local-treatment choices and systemic-treatment roles.
- Keep GTV, CTV, ITV and PTV conceptually separate, then justify each contour using disease extent, motion and setup uncertainty.
- Recognise cord compression and suspected neutropenic sepsis, and explain the treatment that must begin alongside urgent investigation.
- Practise spoken reasoning, image interpretation, plan review and patient explanations alongside MCQs because Final Part B assesses demonstrated clinical skills.
A practical preparation plan
1. Map your examination stage
Use the official curriculum and stage-specific RCR guidance as the complete study map. For First FRCR, organise science study around the published module counts. For Final Part A, cover every listed tumour grouping; for Part B, add practical planning, interpretation and communication work.
2. Build mechanism-to-decision explanations
For each concept, explain the mechanism, the decisive clinical or numerical cue and the tempting alternative. Start with the science concepts, then revisit the same principles in tumour-specific treatment and toxicity decisions.
3. Calculate before checking
Work radiation and statistics examples from a blank page. State units, follow-up periods, geometry and model assumptions before calculating. Record whether an error arose from arithmetic, a reversed ratio, the wrong null value or an invalid assumption.
4. Use the questions diagnostically
Answer the 20 drills independently, then explain why each alternative is less suitable. Sort errors by reasoning gap rather than score alone. Revisit the corresponding concept and reference before attempting the question again after a delay.
5. Practise Final FRCR performance
With suitable supervision, review imaging and contours, critique target and organ doses, and present a concise management recommendation. Rehearse treatment intent, benefits, harms and uncertainty aloud, using teach-back to check whether the explanation works.
6. Expand beyond the selective guide
Use spaced flashcard recall to maintain these foundations, then extend study across the full official outline, including less common tumours and additional acute oncology presentations. Check current candidate guidance separately when planning bookings and examination-day arrangements.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Clinical oncology exams
- Clinical oncology curriculum
- Clinical Oncology Specialty Training Curriculum — August 2026
- FRCR Part 1 (Oncology) — CO1
- FRCR Part 1 (Oncology) — guidance notes for candidates
- Guidance for the first FRCR examination
- Final FRCR Exam (Oncology) — purpose of assessment statement
- FRCR Part 2B (Oncology) — assessment blueprint
- CO2B exam blueprint
- Radiation Biology: A Handbook for Teachers and Students
- Radiation Oncology Physics: A Handbook for Teachers and Students
- MedlinePlus Genetics — Retinoblastoma
- NCI Drug Dictionary — Tamoxifen citrate
- NCI — Hormone Therapy for Breast Cancer
- NCI — Immune Checkpoint Inhibitors
- ICH E9 — Statistical Principles for Clinical Trials
- NCI — Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
- NCI — Prostate Cancer Treatment (PDQ), Health Professional Version
- NCI — Oropharyngeal Cancer Treatment (PDQ), Health Professional Version
- NCI — Sentinel Lymph Node Biopsy
- NCI — Melanoma Treatment (PDQ), Health Professional Version
- NCI — Central Nervous System Tumors Treatment (PDQ), Health Professional Version
- NCI — Cervical Cancer Treatment (PDQ), Health Professional Version
- NCI — Breast Cancer Treatment (PDQ), Health Professional Version
- NCI — Colon Cancer Treatment (PDQ), Health Professional Version
- NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
- NCI — Hodgkin Lymphoma Treatment (PDQ), Health Professional Version
- eviQ — Spinal cord compression palliative EBRT
- AHRQ — Use the Teach-Back Method: Tool 5
- Internal Exposure and Radioactive Materials [MOE]
- clinical-guidance-for-the-management-of-sepsis-including-neutropenic-sepsis.pdf
- download
- KEYTRUDA_imAEs_Guide.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.